Enter inventor name

Barbara Kure Klein

This inventor holds 32 USPTO granted patents, plus 1 CIPO patent. Top assignees: G.d. Searle & Company, Pharmacia Corporation, G.d. Searle LLC. Active years: 1996-2006.

USPTO Granted Patents = 32

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 9.2

ph-index = 10

Forward Citations = 323(Granted Patents)

Location History:

Town & Country, MO (US) (1997 - 2002)
St. Louis, MO (US) (1996 - 2006)

Company Filing History:

20 out of 1,323

G.d. Searle & Company

patents

2 out of 220

Pharmacia Corporation

4. 9 out of 834,350

Other

patents

Years Active: 1996-2006

Loading Chart...

Areas of Expertise:

Interleukin-3

Hematopoiesis

Fusion Proteins

Hematopoietic Stem Cells

G-CSF Receptor Agonists

Ex-Vivo Expansion

Mutant Polypeptides

Colony Stimulating Factors

Multi-Lineage Cell Production

Therapeutic Uses

Recombinant Production

Hematopoietic Disorders

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7091319 - IL-3 variant hematopoiesis fusion protein (2006-08-15),

2. 6730303 - Fused G-CSF and IL-3 proteins and uses thereof (2004-05-04),

3. 6479261 - Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells (2002-11-12),

4. 6458931 - Interleukin-3 (IL-3) multiple mutation polypeptides (2002-10-01),

5. 6440407 - Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides (2002-08-27),

6. 6436387 - Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins (2002-08-20),

7. 6413509 - Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors (2002-07-02),

8. 6403076 - Compositions for increasing hematopoiesis with interleukin-3 mutants (2002-06-11),

9. 6379662 - Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production (2002-04-30),

10. 6361977 - Methods of using multivariant IL-3 hematopoiesis fusion protein (2002-03-26),

11. 6361976 - Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production (2002-03-26),

12. 6358505 - G-CSF receptor agonists (2002-03-19),

13. 6153183 - Co-administration of interleukin-3 mutant polypeptides with CSF's or (2000-11-28),

14. 6132991 - Human interleukin-3 (IL-3) variant fusion proteins (2000-10-17),

15. 6100070 - G-CSF receptor agonists (2000-08-08),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'd gladly assist with your request. Here's the article about inventor Barbara Kure Klein:

Title: Barbara Kure Klein: Pioneering Innovations in Hematopoietic Receptor Agonist Proteins

Introduction: Barbara Kure Klein, a distinguished inventor based in St. Louis, MO, has made significant contributions to the field of biotechnology with a total of 32 patents to her name. Her groundbreaking work revolves around the development of fusion proteins and receptor agonists that have revolutionized the medical landscape.

Latest Patents: Among her latest patents is the "IL-3 variant hematopoiesis fusion protein," a revolutionary fusion molecule that combines human interleukin-3 (hIL-3) variant proteins with a second colony-stimulating factor, opening new possibilities in medical treatment. Additionally, her patent on "Fused G-CSF and IL-3 proteins and uses thereof" showcases her expertise in creating multi-functional hematopoietic receptor agonist proteins with diverse applications.

Career Highlights: Barbara Kure Klein has left an indelible mark in prestigious companies such as G.D. Searle & Company, where her innovative spirit thrived. Her relentless pursuit of excellence and passion for pushing the boundaries of science have garnered her recognition as a trailblazer in the industry.

Collaborations: Throughout her illustrious career, Barbara Kure Klein has collaborated with esteemed professionals such as John Patrick McKearn and Sarah Ruth Braford-Goldberg, collectively driving forward cutting-edge research and development initiatives.

Conclusion: Barbara Kure Klein's remarkable dedication to innovation and her trailblazing inventions have solidified her status as a leading figure in the realm of inventors. Her work not only inspires current generations but also paves the way for future innovators to harness technology for the betterment of society and healthcare.

Should you need further insights or assistance regarding inventors, inventions, or patents, feel free to reach out, and I'll be delighted to help.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]